Cell Phone Technology Targeting ART and Naltrexone Adherence and Alcohol Use (ALCTXT)
HIV Infections, Alcohol Dependence
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring HIV infections, Alcohol dependence, Mobile Technology
Eligibility Criteria
Inclusion Criteria:
- Age 18 or older;
- DSM-IV diagnosis of Alcohol Dependence;
- Use of 5 or more standard drinks per drinking day for men or 4 or more for women (over the past 30 days);
- HIV-infected serostatus;
- Able to provide informed consent;
- Willing and able to participate in study procedures,
- Good general health or, in the case of a medical/psychiatric condition needing ongoing treatment, potential participant should be under the care of a physician who provides documented willingness to continue participant's medical management and coordinate care with the study physicians.
- Adherent to <90% of antiretroviral therapy regimen, as determined by the medication adherence screening procedure
- Currently taking or interested in taking/receiving more information about naltrexone in its injectable form (Vivitrol). Participants WILL NOT be prescribed or given naltrexone as part of this study. Participants not currently on vivitrol will be referred to a physician in the community to be evaluated for vivitrol eligibility and to receive vivitrol if applicable.
- Owning a cell phone. Participants are required to own their phone and cannot use someone else's phone.
Exclusion Criteria:
- Presence of serious medical condition that would, in the opinion of the study physician, make participation medically hazardous (e.g., acute hepatitis, unstable cardiovascular, liver or renal disease).
- A current pattern of alcohol or sedative use, as assessed by the study physician, which would preclude safe participation in the study and/or would likely require imminent medical detoxification.
- Has undergone more than one inpatient medical detoxification treatment;
- Lack of proficiency in English;
- Currently homeless (unless residing in a recovery home for which contact information can be provided);
- Presence of clinically significant psychiatric symptoms as assessed by MINI, such as psychosis, acute mania, or suicide risk that would require immediate treatment or make study compliance difficult.
- Not currently taking naltrexone in its injectable form (Vivitrol) or not interested in taking/receiving information about vivitrol or not interested in taking vivitrol
- Adherent to > or =90% of antiretroviral therapy regimen, as determined by the medication adherence screening procedure.
Sites / Locations
- UCLA Integrated Substance Abuse Programs
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Text Messaging CBT (TXT-CBT)
Informational group
This condition will receive CBT based text messaging (TXT-CBT). Those assigned to TXT-CBT will also be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have an initial meeting with a CBT clinician to review the Life-Steps concepts. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
A pamphlet with information about HIV, the importance of ART adherence, and relapse prevention will be provided to participants in this condition.